Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on RNA interference (RNAi) therapeutics. Its marketed products include AMVUTTRA for hereditary transthyretin-mediated amyloidosis with polyneuropathy, ONPATTRO for polyneuropathy of hATTR amyloidosis, GIVLAARI for acute hepatic porphyria, OXLUMO for primary hyperoxaluria type 1, and Leqvio, developed with Novartis, for hypercholesterolemia or mixed dyslipidemia. The company also develops treatments for complement-mediated diseases, alpha-1 liver disease, and other conditions, including Cemdisiran, Belcesiran, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, and Fitusiran. The ALNY YTD return is shown above.
The YTD Return on the ALNY YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ALNY YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ALNY YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|